Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824123 | 0.89 | RECQL (0.57) | EPHX1EPHX2SMN1; SMN2TP53NFKB1 | |
| SCHEMBL2828179 | 0.86 | LMNA (0.54) | EPHX1EPHX2SMN1; SMN2TP53NFKB1 | |
| SCHEMBL2829351 | 0.82 | MAPT (0.49) | SMN1; SMN2TP53ALDH1A1RAB9A | |
| SCHEMBL2830941 | 0.82 | L3MBTL1 (0.56) | ALDH1A1RAB9A | |
| SCHEMBL2827804 | 0.82 | MEN1 (0.52) | EPHX1EPHX2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2828592 | 0.80 | MAPT (0.44) | SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL2829128 | 0.80 | CNR1 (0.48) | EPHX2SMN1; SMN2 | |
| SCHEMBL2830726 | 0.78 | NAMPT (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL2829706 | 0.78 | DRD4 (0.59) | ALDH1A1RAB9AGAADGAT1 | |
| SCHEMBL2829597 | 0.77 | NPC1 (0.51) | SMN1; SMN2TP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-101068786-A | 3-substituted pyridine derivatives as h3 antagonists | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | claimed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | claimed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | claimed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | claimed |
| EP-1824829-B1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7528135-B2 | Pyridine derivatives as H3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| CN-101068786-A | 3-substituted pyridine derivatives as h3 antagonists | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| EP-1824829-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | US | disclosed |
| WO-2006058649-A1 | 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122187-A1 | Pyridine derivatives as H3 antagonists | HRH3, HRH4, HRH2 | EPHX1 840/4885EPHX2 1363/4885SMN1; SMN2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.